title: Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation.
abstract: BACKGROUND
  Although secondary acute leukemias and myelodysplasia are the known complications of adjuvant chemotherapy for breast cancer, the treatment outcome of these secondary malignancies is presently unclear. We examined the clinical and pathological features as well as the treatment results of a series of patients with acute leukemia/myelodysplasia arising after adjuvant chemotherapy for breast cancer.
  
  
  METHODS
  Patients referred to our institution during a 5-year period for treatment of acute leukemia/myelodysplasia and who had received adjuvant chemotherapy for breast cancer are included. Leukemia-free survival for the whole group and for patients who underwent hematopoietic stem cell transplantation (HSCT) was estimated.
  
  
  RESULTS
  Fifteen women (14 with acute leukemia and one with myelodysplasia) were identified. Seven of 15 patients had received an anthracycline, cyclophosphamide and a taxane. Ten patients developed acute leukemia/myelodysplasia with a latency period of 2 years or less from initiation of chemotherapy. Although mixed-lineage leukemia (MLL) rearrangement was the commonest chromosomal abnormality (8 of 15 patients), various other chromosomal abnormalities were also detected. Twelve of 15 patients underwent HSCT (11 allogeneic and one autologous). Eleven of these 12 patients who underwent HSCT were in remission at a median follow-up of 20.4 months (range 4.4-53.3 months).
  
  
  CONCLUSIONS
  Durable remissions can be achieved in patients who develop acute leukemia/myelodysplasia secondary to adjuvant chemotherapy for breast cancer and are able to undergo allogeneic HSCT. Our results indicate that HSCT should be an early consideration in the management of such patients who are suitable candidates for the procedure.
authors: Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA. vpullarkat@coh.org
authors: V
authors: V
authors: Pullarkat
authors: M L
authors: ML
authors: Slovak
authors: A
authors: A
authors: Dagis
authors: V
authors: V
authors: Bedell
authors: G
authors: G
authors: Somlo
authors: R
authors: R
authors: Nakamura
authors: A S
authors: AS
authors: Stein
authors: M R
authors: MR
authors: O'Donnell
authors: A
authors: A
authors: Nademanee
authors: A L
authors: AL
authors: Teotico
authors: S
authors: S
authors: Bhatia
authors: S J
authors: SJ
authors: Forman
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000601:surgery*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000601:surgery*; D012074:Remission Induction